-
ASSESSING THE PSYCHOMETRIC PROPERTIES OF TWO INSTRUMENTS MEASURING ATTITUDES TOWARDS AI AND THEIR ASSOCIATED FACTORS
Mar 18, 2026, 21:38 PM -
STATIN INITIATION TIME AFTER GRAVES' DISEASE DIAGNOSIS AND THE RISK OF GRAVES' ORBITOPATHY: A ONE-YEAR LANDMARK ANALYSIS
Mar 18, 2026, 21:38 PM -
REAL-WORLD SAFETY OF XANOMELINE/TROSPIUM CHLORIDE IN SCHIZOPHRENIA MANAGEMENT
Mar 18, 2026, 21:38 PM -
ANALYSIS OF HOSPITAL LENGTH OF STAY IN HONG KONG: EFFECTS OF AGE, CONDITIONS, AND COMORBIDITY INTERACTIONS
Mar 18, 2026, 21:38 PM -
BAYESIAN MULTI-PARAMETER EVIDENCE SYNTHESIS FOR INFORMED EXTRAPOLATIONS OF TIME-TO-EVENT OUTCOMES IN MULTISTATE MODELS
Mar 18, 2026, 21:38 PM -
DETERMINANTS OF DELAY IN EGFR INHIBITOR INITIATION AND ITS IMPACT ON CLINICAL OUTCOMES IN NON-SMALL CELL LUNG CANCER PATIENTS
Mar 18, 2026, 21:38 PM -
ALIGNING PATIENTS ACROSS ARMS: WHY COMMON RANDOM NUMBERS IMPROVE EFFICIENCY IN PARTITIONED SURVIVAL MODELS
Mar 18, 2026, 21:38 PM -
IMPACT OF TIME-VARYING RELAPSE RISK ON LONG-TERM COST-EFFECTIVENESS OUTCOMES IN CHRONIC RELAPSING DISEASES
Mar 18, 2026, 21:38 PM -
HUMANISTIC BURDEN IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD) USING PATIENT-REPORTED OUTCOME MEASURES (PROMS)
Mar 18, 2026, 21:38 PM -
HEALTHCARE RESOURCE UTILIZATION (HRU) AND COST BURDEN IN NON-METASTATIC MELANOMA IN THE MODERN TREATMENT ERA: A SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER)-MEDICARE ANALYSIS
Mar 18, 2026, 21:38 PM -
ASSESSING THE VALUE OF LOST SCHOOLING DUE TO ILLNESS AMONG CHILDREN IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF PROCALCITONIN-GUIDED ANTIBIOTIC THERAPY IN ADULT PATIENTS WITH ACUTE RESPIRATORY INFECTION IN A COLOMBIAN REFERRAL HOSPITAL
Mar 18, 2026, 21:38 PM -
MODELLING HEALTH SYSTEM CAPACITY AND MEASUREMENT DISPERSION TO EXPLAIN CROSS-NATIONAL VARIATION IN EQVT UTILITY VALUES
Mar 18, 2026, 21:38 PM -
A SYSTEMATIC REVIEW OF FINDINGS AND METHODS IN ECONOMIC EVALUATIONS OF DYADIC HEALTHCARE INTERVENTIONS
Mar 18, 2026, 21:38 PM -
THE COST-EFFECTIVENESS OF CONTINUOUS GLUCOSE MONITORING (CGM) FOR ADULTS WITH TYPE 1 DIABETES IN IRELAND
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF SEMAGLUTIDE 2.4 MG COMPARED WITH RESMETIROM AND STANDARD OF CARE FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) IN THE U.S. USING MOST FAVORED NATION (MFN) PRICING
Mar 18, 2026, 21:38 PM -
REAL-WORLD DIAGNOSTIC DELAY, TREATMENT ACCESS, AND HEALTH SYSTEM BURDEN IN PRIMARY IMMUNODEFICIENCY/INBORN ERRORS OF IMMUNITY: EVIDENCE FROM THE UNITED STATES AND EX-US SETTINGS
Mar 18, 2026, 21:38 PM -
WHEN IS REAL-WORLD EVIDENCE SCIENTIFICALLY SOUND? EXPERT CONSENSUS ON SASS FOR CFL COMMUNICATION
Mar 18, 2026, 21:38 PM -
OBSERVED CARDIOVASCULAR DISEASE PREVALENCE AMONG OBESE AND TYPE 2 DIABETES PATIENTS WITH AND WITHOUT GLP-1 TREATMENT
Mar 18, 2026, 21:38 PM -
THE EXTENT OF TREATMENT RESPONSE AND PREFERENCE HETEROGENEITY IN MAJOR DEPRESSIVE DISORDER: IMPLICATIONS FOR POPULATION-LEVEL RESOURCE ALLOCATION
Mar 18, 2026, 21:38 PM
